Phathom Pharmaceuticals, Inc. (PHAT) NASDAQ
9.65
+0.41(+4.44%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Phathom Pharmaceuticals, Inc.
Address
100 Campus Drive
Florham Park, NJ 07932
United States of America (the)
Phone
877 742 8466
Sector
Healthcare
Industry
Biotechnology
Employees
427
First IPO Date
October 25, 2019
Key Executives
| Name | Title | Pay | Year Born |
| Steven L. Basta | Chief Executive Officer, President & Director | 1.17M | 1966 |
| Sanjeev Narula | Chief Financial & Business Officer | 644,285 | 1962 |
| Anne Marie Cook | Chief Legal Officer & Corporate Secretary | 663,406 | 1962 |
| Azmi Nabulsi | Co-Founder | 1.95M | 1960 |
| David A. Socks | Co-Founder | 1.95M | 1975 |
| Jay Buchanan | Senior VP of Manufacturing & Supply Chain | 0 | N/A |
| Bill Aprea | Senior Vice President, Chief Compliance Officer & Deputy Chief Legal Officer | 0 | N/A |
| Eric Sciorilli | Director of Business Development & Investor Relations | 0 | N/A |
| Jonathan Bentley | Senior Vice President and Head of Sales, Operations & Training | 0 | N/A |
| Paul Cocja | Chief People Officer | 0 | N/A |
| Robert Breedlove | Vice President of Finance & Principal Accounting Officer | 0 | N/A |
| Nancy R. Phelan | Senior Vice President of Marketing & Analytics | 0 | 1969 |
| Eckhard Leifke | Chief Medical Officer | 0 | N/A |
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
